Kisqali is a modern targeted therapy used in the treatment of HR-positive / HER2-negative advanced or metastatic breast cancer. It is part of the CDK4/6 inhibitor class, which represents a major advancement in oncology care.
What is Kisqali ?
Kisqali belongs to a group of drugs called CDK4/6 inhibitors, which control cell division and growth.
In hormone-positive breast cancer, these signals become overactive, leading to uncontrolled tumor growth. Kisqali works by:
- Slowing down cancer cell division
- Reducing tumor progression
- Improving long-term disease control
In simple terms:
It helps stop cancer cells from multiplying.
Indications
Kisqali (Ribociclib) is used in:
- HR-positive breast cancer
- HER2-negative cases
- Advanced or metastatic disease
- In combination with hormonal therapy such as Letrozole or Fulvestrant
Dosage and Administration
- Common dose: 200 mg or as prescribed by the physician
- Taken orally
- Standard cycle: 21 days on treatment + 7 days off
- Should be taken at the same time every day
Common Side Effects
- Low white blood cell count (neutropenia)
- Fatigue
- Nausea
- Mild hair thinning
- Skin rash
- Rarely: heart rhythm or liver function changes
Regular monitoring is required during treatment.
Availability in Egypt
Kisqali (Ribociclib) is available in specialized oncology centers and major pharmacies in Egypt. It is a high-cost medication that requires close medical supervision.
Kisqali (Ribociclib) 200 mg is an important targeted therapy for HR-positive / HER2-negative breast cancer, helping to slow tumor growth and improve disease control in advanced stages.
Medical Disclaimer: This content is for educational purposes only and does not replace professional medical advice.
